Medical Research Council Laboratories, Fajara, The Gambia.
Rev Med Virol. 2013 Jul;23(4):221-40. doi: 10.1002/rmv.1739. Epub 2013 Feb 26.
HIV-1 and HIV-2 share many similarities including their basic gene arrangement, modes of transmission, intracellular replication pathways and clinical consequences: both result in AIDS. However, HIV-2 is characterised by lower transmissibility and reduced likelihood of progression to AIDS. The underlying mechanistic differences between these two infections illuminate broader issues of retroviral pathogenesis, which remain incompletely understood. Comparisons between these two infections from epidemiological, clinical, virologic and immunologic viewpoints provide a basis for hypothesis generation and testing in this 'natural experiment' in viral pathogenesis. In terms of epidemiology, HIV-2 remains largely confined to West Africa, whereas HIV-1 extends worldwide. Clinically, HIV-2 infected individuals seem to dichotomise, most remaining long-term non-progressors, whereas most HIV-1 infected individuals progress. When clinical progression occurs, both diseases demonstrate very similar pathological processes, although progression in HIV-2 occurs at higher CD4 counts. Plasma viral loads are consistently lower in HIV-2, as are average levels of immune activation. Significant differences exist between the two infections in all components of the immune system. For example, cellular responses to HIV-2 tend to be more polyfunctional and produce more IL-2; humoral responses appear broader with lower magnitude intratype neutralisation responses; innate responses appear more robust, possibly through differential effects of tripartite motif protein isoform 5 alpha. Overall, the immune response to HIV-2 appears more protective against disease progression suggesting that pivotal immune factors limit viral pathology. If such immune responses could be replicated or induced in HIV-1 infected patients, they might extend survival and reduce requirements for antiretroviral therapy.
HIV-1 和 HIV-2 有许多相似之处,包括它们的基本基因排列、传播方式、细胞内复制途径和临床后果:两者都导致艾滋病。然而,HIV-2 的传染性较低,进展为艾滋病的可能性也较小。这两种感染之间的潜在机制差异阐明了更广泛的逆转录病毒发病机制问题,这些问题仍未得到完全理解。从流行病学、临床、病毒学和免疫学观点比较这两种感染,为在病毒发病机制的这种“自然实验”中产生和检验假说提供了基础。在流行病学方面,HIV-2 仍然主要局限于西非,而 HIV-1 则扩展到全球。从临床角度来看,HIV-2 感染的个体似乎呈两极分化,大多数长期保持非进展者,而大多数 HIV-1 感染的个体则进展。当临床进展发生时,两种疾病都表现出非常相似的病理过程,尽管 HIV-2 的进展发生在更高的 CD4 计数时。HIV-2 的血浆病毒载量始终较低,免疫激活的平均水平也较低。两种感染在免疫系统的所有成分中都存在显著差异。例如,对 HIV-2 的细胞反应往往更具多功能性,产生更多的 IL-2;体液反应似乎更广泛,同种型中和反应的幅度较低;先天反应似乎更强大,可能通过三部分基序蛋白 5 型异构体的不同作用。总的来说,对 HIV-2 的免疫反应似乎更能保护免受疾病进展,表明关键的免疫因素限制了病毒病理学。如果在 HIV-1 感染患者中可以复制或诱导这种免疫反应,它们可能会延长生存时间并减少对抗逆转录病毒治疗的需求。